Logotipo del SMU


Uruguayan Medical Journal

ISSN: 1688-0390

Vol.31 - Nº 2 - Jun. 2015

Previous Art | Index | Next Art

Hydroxychloroquine during pregnancy and breastfeeding

Rev Med Urug 2015; 31: 128-132
Full text (spanish) |  Full text (spanish) (New windows, pdf) | Abstract


Treating patients with systemic autoinmune diseases during pregnancy and breastfeeding may be complex and results in a challenge for professionals responsible for them.

There is evidence about the benefits of hydroxychloroquine (HCQ) with an adequate margin of safety in patients with this condition.

This update aims to describe effectiveness and safety of HCQ in the treatment of systemic autoinmune diseases during pregnancy and breastfeeding.

It has been proved that the use of HCQ during pregnancy reduces systemic lupus erythematosus (SLE) activity, the risk of a lupus flare up, as well as the requirements of glucocorticoids during pregnancy and breastfeeding.

Discontinuing antimalarial treatment during pregnancy is deleterious for both the mother and the fetus.

No tetratogenic effects or retinal harm have been found to be caused by HCQ in the children of mothers exposed to this treatment during such period.

In conclusion, the treatment with HCQ during pregnancy and breastfeeding is effective and has adequate safety margins. Thus, it must continue to be used during this period.